| Literature DB >> 21704313 |
Anna Almén-Christensson1, Mats Hammar, Lotta Lindh-Åstrand, Anne-Marie Landtblom, Jan Brynhildsen.
Abstract
The effect of treatment with percutaneous E(2) (100 μg/24 h) during 2 weeks perimenstrually on the number and severity of menstrual migraine attacks was studied in 27 women in a randomized, placebo-controlled, double-blind, crossover trial. We were not able to demonstrate any difference between E(2) supplementation and placebo on the number or severity of migraine attacks, but both regimens showed significant effects compared with before treatment. CLINICAL TRIAL IDENTIFICATION NUMBER: NCT00204074.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21704313 DOI： 10.1016/j.fertnstert.2011.05.089
Source DB: PubMed Journal: Fertil Steril ISSN： 0015-0282 Impact factor: 7.329